Detalhe da pesquisa
1.
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Br J Haematol;
204(4): 1293-1299, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38263627
2.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Haematologica;
109(3): 777-786, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37731379
3.
The role of therapeutic plasma exchange in plasma cell disorders.
Ann Hematol;
2024 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38558184
4.
Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation.
Am J Hematol;
99(6): 1205-1207, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38602288
5.
External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
Br J Haematol;
201(2): 280-284, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36604838
6.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience.
Haematologica;
2023 10 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37855036
7.
Intravenous immunoglobulin prophylaxis is associated with decreased rate of infection-related hospitalizations in multiple myeloma patients.
Hematol Oncol;
41(4): 718-724, 2023 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37231908
8.
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
Future Oncol;
19(1): 7-17, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36779512
9.
Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.
Eur J Haematol;
109(4): 309-320, 2022 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35770616
10.
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring.
J Oncol Pharm Pract;
: 10781552221104422, 2022 Jun 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35673764
11.
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.
Br J Haematol;
193(6): 1213-1219, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33997961
12.
Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Ann Hematol;
100(9): 2155-2172, 2021 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34318356
13.
Validation of the GATMO score in predicting non-relapse mortality following hematopoietic cell transplant in multiple myeloma patients.
Eur J Haematol;
112(2): 314-316, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37804053
14.
Progression with clinical features is associated with worse subsequent survival in multiple myeloma.
Am J Hematol;
94(4): 439-445, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30663805
15.
Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation.
J Clin Apher;
34(6): 638-645, 2019 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31381194
16.
Validation of the role of corrected DLCO in predicting outcomes post autologous hematopoietic cell transplant for multiple myeloma.
Eur J Haematol;
110(6): 780-783, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36949569
17.
Daratumumab monotherapy for relapsed POEMS syndrome.
Am J Hematol;
98(11): E291-E294, 2023 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37548551
18.
Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days.
J Clin Apher;
33(3): 303-309, 2018 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29134688
19.
Simple modifications of therapeutic plasma exchange treatments during the SARS-CoV-2 pandemic.
Transfusion;
61(3): 671-672, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33368305
20.
Daratumumab proves safe and highly effective in AL amyloidosis.
Br J Haematol;
185(2): 342-344, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29938774